This sectionis missing information about the entire 1207-aa long gene product: the pro-pre-EGF; what happens if things go wrong (renal hypomagnesemia 4, OMIM 611718). Please expand the section to include this information. Further details may exist on thetalk page.(December 2023)
EGF, via binding toits cognate receptor, results in cellular proliferation, differentiation, and survival.[10]
Salivary EGF, which seems to be regulated by dietary inorganiciodine, also plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents.[8]
EGF is the founding member of theEGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. Besides EGF itself other family members include:[16]
This sequence contains six cysteine residues that form three intramoleculardisulfide bonds. Disulfide bond formation generates three structural loops that are essential for high-affinity binding between members of the EGF-family and theircell-surface receptors.[5]
Recombinant human epidermal growth factor, sold under the brand nameHeberprot-P, is used to treatdiabetic foot ulcers. It can be given by injection into the wound site,[19] or may be used topically.[20] Tentative evidence shows improved wound healing.[21] Safety has been poorly studied.[21]
EGF is used to modify synthetic scaffolds for manufacturing ofbioengineered grafts by emulsionelectrospinning or surface modification methods.[22][23]
EGF plays an enhancer role on the osteogenic differentiation ofdental pulp stem cells (DPSCs) because it is capable of increasing extracellular matrix mineralization. A low concentration of EGF (10 ng/ml) is sufficient to induce morphological and phenotypic changes. These data suggests that DPSCs in combination with EGF could be an effective stem cell-based therapy tobone tissue engineering applications inperiodontics andoral implantology.[24]
^Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS (2005).Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders.ISBN978-0-7216-0187-8.
^abChao J (2013-01-01), Rawlings ND, Salvesen G (eds.), "Chapter 624 - Mouse Kallikrein 9, Epidermal Growth Factor-binding Protein",Handbook of Proteolytic Enzymes (Third ed.), Academic Press, pp. 2830–2831,doi:10.1016/b978-0-12-382219-2.00624-4,ISBN978-0-12-382219-2
^Fallon JH, Seroogy KB, Loughlin SE, Morrison RS, Bradshaw RA, Knaver DJ, et al. (June 1984). "Epidermal growth factor immunoreactive material in the central nervous system: location and development".Science.224 (4653):1107–9.Bibcode:1984Sci...224.1107F.doi:10.1126/science.6144184.PMID6144184.
^abDreux AC, Lamb DJ, Modjtahedi H, Ferns GA (May 2006). "The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis".Atherosclerosis.186 (1):38–53.doi:10.1016/j.atherosclerosis.2005.06.038.PMID16076471.
^Stortelers C, Souriau C, van Liempt E, van de Poll ML, van Zoelen EJ (July 2002). "Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display".Biochemistry.41 (27):8732–41.doi:10.1021/bi025878c.PMID12093292.
^Yang S, Geng Z, Ma K, Sun X, Fu X (June 2016). "Efficacy of Topical Recombinant Human Epidermal Growth Factor for Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis".The International Journal of Lower Extremity Wounds.15 (2):120–5.doi:10.1177/1534734616645444.PMID27151755.S2CID43897291.
Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P (May 1995). "The epidermal growth factor".Cell Biology International.19 (5):413–30.doi:10.1006/cbir.1995.1086.PMID7640657.S2CID20186286.
Dvorak B (March 2004). "Epidermal growth factor and necrotizing enterocolitis".Clinics in Perinatology.31 (1):183–92.doi:10.1016/j.clp.2004.03.015.PMID15183666.
